Third Rock Ventures

Third Rock Ventures

neurons.AI

BMS joins forces with insitro to develop neurodegenerative treatments

Xconomy

Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B

Pulse 2.0

Casma Therapeutics Raises $50 Million In Series B

$50,000,000 Venture capital (Series B)
FinSMEs , WSJ Venture Capital

Casma Therapeutics Raises $50M in Series B Financing

MedCity News

FDA green-lights second RET inhibitor, this time from Blueprint Medicines

Pulse 2.0

Targeted Cancer Therapy Biotech Company Tango Therapeutics Raises $50 Million 

Xconomy

Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor

$50,000,000 Venture capital
FinSMEs

Tango Therapeutics Raises $50M in Equity Financing

Xconomy

Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia

MedCity News

Relay Therapeutics prices IPO at $400M

Bloomberg Technology

SoftBank-Backed Relay Therapeutics Seeks $265 Million in IPO

MedCity News

Protein motion-focused Relay Therapeutics files for $200M IPO

$143,000,000 Venture capital (Series B)
FinSMEs , neurons.AI , PrivateEquityWire , +1

insitro Raises $143M in Series B Financing

Xconomy

MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021

$60,000,000 Venture capital (Series B)
Pulse 2.0

Targeted Cancer Therapies Company Tango Closes $60 Million

FinSMEs

Flagship Pioneering Closes $1.1 Billion Capital Raise

$145,600,000 Venture capital (Series C)
FinSMEs , Pulse 2.0 , MedCity News

Element Science Secures $145.6M in Series C Financing

Xconomy

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

MedCity News

Flagship Pioneering launches fertility-focused Ohana Biosciences

Xconomy

Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus